Search Results

Charles River Laboratories International, Inc. today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement.

FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology.

Charles River Laboratories International, Inc. today announced a plasmid DNA and retrovirus vector production program agreement.

New turnkey research facility will provide AAALAC-accredited flexible vivarium space for Massachusetts biopharmaceutical hub Charles River Laboratories International, Inc. has announced the opening of a new Charles River Accelerator and Development Lab facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc. today announced an AAV9 production program agreement.

Charles River Laboratories International, Inc. and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox family biologics, announced a Good Manufacturing Practice- plasmid DNA contract development and manufacturing organization agreement.